SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368:40418.
  • 2
    Morgan MD, Harper L, Williams J, Savage C. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol 2006; 17:122434.
  • 3
    Woywodt A, Streiber F, De Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361:20610.
  • 4
    Xiao H, Heeringa P, Liu Z et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167:3945.
  • 5
    Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:411519.
  • 6
    Csernok E, Ludemann J, Gross WL, Bainton DF. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 1990; 137:111320.
  • 7
    Gilligan HM, Bredy B, Brady HR et al. Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996; 184:223141.
  • 8
    Finkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:61119.
  • 9
    Wiik A. Autoantibodies in vasculitis. Arthritis Res Ther 2003; 5:14752.
  • 10
    Abdgawad M, Hellmark T, Gunnarsson L, Westman KW, Segelmark M. Increased neutrophil membrane expression and plasma level of proteinase 3 in systemic vasculitis are not a consequence of the −564 A/G promotor polymorphism. Clin Exp Immunol 2006; 145:6370.
  • 11
    Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 1995; 374:2933.
  • 12
    Schreiber A, Otto B, Ju X et al. Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils. J Am Soc Nephrol 2005; 16:221624.
  • 13
    Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3–ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:22328.
  • 14
    Von Vietinghoff S, Tunnemann G, Eulenberg C et al. NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils. Blood 2007; 109:448793.
  • 15
    Bauer S, Abdgawad M, Gunnarsson L, Segelmark M, Tapper H, Hellmark T. Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol 2007; 81:45864.
  • 16
    Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene 2002; 21:337790.
  • 17
    Edvardsson L, Dykes J, Olsson ML, Olofsson T. Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine-stimulated CD34+ human marrow cells in vitro. Br J Haematol 2004; 127:45163.
  • 18
    Garwicz D, Lennartsson A, Jacobsen SE, Gullberg U, Lindmark A. Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model. Haematologica 2005; 90:3844.
  • 19
    Missen MA, Haylock D, Whitty G, Medcalf RL, Coughlin PB. Stage specific gene expression of serpins and their cognate proteases during myeloid differentiation. Br J Haematol 2006; 135:71524.
  • 20
    Theilgaard-Monch K, Jacobsen LC, Borup R et al. The transcriptional program of terminal granulocytic differentiation. Blood 2005; 105:178596.
  • 21
    Stroncek DF. Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. Curr Opin Hematol 2007; 14:68893.
  • 22
    Brachemi S, Mambole A, Fakhouri F et al. Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies. J Am Soc Nephrol 2007; 18:23309.
  • 23
    Jenne DE, Kuhl A. Production and applications of recombinant proteinase 3, Wegener's autoantigen: problems and perspectives. Clin Nephrol 2006; 66:1539.
  • 24
    Specks U. What you should know about PR3–ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Res 2000; 2:2637.
  • 25
    Rao NV, Rao GV, Marshall BC, Hoidal JR. Biosynthesis and processing of proteinase 3 in U937 cells. Processing pathways are distinct from those of cathepsin G. J Biol Chem 1996; 271:29728.
  • 26
    Skold S, Rosberg B, Gullberg U, Olofsson T. A secreted proform of neutrophil proteinase 3 regulates the proliferation of granulopoietic progenitor cells. Blood 1999; 93:84956.
  • 27
    Fujinaga M, Chernaia MM, Halenbeck R, Koths K, James MN. The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies. J Mol Biol 1996; 261:26778.
  • 28
    Skold S, Zeberg L, Gullberg U, Olofsson T. Functional dissociation between proforms and mature forms of proteinase 3, azurocidin, and granzyme B in regulation of granulopoiesis. Exp Hematol 2002; 30:68996.
  • 29
    Specks U, Fass DN, Fautsch MP, Hummel AM, Viss MA. Recombinant human proteinase 3, the Wegener's autoantigen, expressed in HMC-1 cells is enzymatically active and recognized by c-ANCA. FEBS Lett 1996; 390:26570.
  • 30
    Witko-Sarsat V, Halbwachs-Mecarelli L, Almeida RP et al. Characterization of a recombinant proteinase 3, the autoantigen in Wegener's granulomatosis and its reactivity with anti-neutrophil cytoplasmic autoantibodies. FEBS Lett 1996; 382:1306.
  • 31
    Van Der Geld YM, Oost-Kort W, Limburg PC, Specks U, Kallenberg CG. Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methodsods 2000; 244:11731.
  • 32
    Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 1989; 59:95968.
  • 33
    Schreiber A, Luft FC, Kettritz R. Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int 2004; 65:217283.
  • 34
    Kjeldsen L, Sengelov H, Borregaard N. Subcellular fractionation of human neutrophils on Percoll density gradients. J Immunol Methods 1999; 232:13143.
  • 35
    Van Der Geld YM, Limburg PC, Kallenberg CG. Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies. Clin Exp Immunol 1999; 118:48796.
  • 36
    Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000; 110:1828.
  • 37
    Le Cabec V, Cowland JB, Calafat J, Borregaard N. Targeting of proteins to granule subsets is determined by timing and not by sorting: the specific granule protein NGAL is localized to azurophil granules when expressed in HL-60 cells. Proc Natl Acad Sci USA 1996; 93:64547.
  • 38
    Goldschmeding R, Van Dalen CM, Faber N et al. Further characterization of the NB 1 antigen as a variably expressed 56–62 kD GPI-linked glycoprotein of plasma membranes and specific granules of neutrophils. Br J Haematol 1992; 81:33645.
  • 39
    Goldschmeding R, Van Der Schoot CE, Ten Bokkel Huinink D et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84:157787.
  • 40
    Campbell EJ, Campbell MA, Owen CA. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol 2000; 165:336674.
  • 41
    Korkmaz B, Attucci S, Jourdan ML, Juliano L, Gauthier F. Inhibition of neutrophil elastase by alpha1-protease inhibitor at the surface of human polymorphonuclear neutrophils. J Immunol 2005; 175:332938.
  • 42
    Rice WG, Weiss SJ. Regulation of proteolysis at the neutrophil–substrate interface by secretory leukoprotease inhibitor. Science 1990; 249:17881.
  • 43
    Tapper H, Kallquist L, Johnsson E, Persson AM, Hansson M, Olsson I. Neutrophil elastase sorting involves plasma membrane trafficking requiring the C-terminal propeptide. Exp Cell Res 2006; 312:347184.
  • 44
    Schreiber A, Busjahn A, Luft FC, Kettritz R. Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14:6875.
  • 45
    Witko-Sarsat V, Lesavre P, Lopez S et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10:122433.
  • 46
    Matsumoto T, Kaneko T, Wada H et al. Proteinase 3 expression on neutrophil membranes from patients with infectious disease. Shock 2006; 26:12833.
  • 47
    Rarok AA, Huitema MG, Van Der Leij MJ et al. Recombinant protein to analyze autoantibodies to proteinase 3 in systemic vasculitis. Am J Clin Pathol 2003; 120:58695.
  • 48
    Sun J, Fass DN, Viss MA et al. A proportion of proteinase 3 (PR3) -specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol 1998; 114:3206.
  • 49
    Farrag L, Pendergraft WF 3rd, Yang JJ, Jennette JC, Falk RJ, Preston GA. A study of conformational restraints on reactivity of human PR3-specific autoantibodies (ANCA) facilitated through protein folding manipulations of a new recombinant proteinase 3 protein. Autoimmunity 2007; 40:50311.
  • 50
    Russell KA, Fass DN, Specks U. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44:4638.